当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Sana Kovazki
Background: Antipathetic responses have been reported with mRNA vaccines for COVID- 19 forestalment. Cases perceived to be at advanced threat for a response may be appertained to an allergist, although evaluation strategies may differ between allergists [1, 2].
Objective: Our end was to determine issues of COVID- 19 vaccinations in cases estimated by an allergist using different approaches.
Method: We conducted a retrospective case series evaluation of 98 cases seen at the University of Michigan Allergy Clinic for enterprises regarding COVID- 19 vaccination. Of these 98 cases, 34 passed skin testing with polyethylene glycol( cut) 2000 with or without cut 3350/ polysorbate 80 testing.
Results: Of the 34 cases on whom skin testing was performed, 16 passed testing before vaccination and 18 passed testing after a reported vaccine- related event. One case had a positive skin testing result in response to cut 3350 following a vaccination response and natural infection and was advised against a alternate cure. One case with a significant history concerning of anaphylaxis in response to cut had positive results of testing to identify mislike to cut 2000, cut 3350, and polysorbate 80 and was advised against vaccination. Of the 98 cases, 63( 64) permitted COVID- 19 vaccination without complication after evaluation by an allergist.
Conclusion: No significant differences were set up between vaccination comforting with and without skin testing to excipients. Cases who presented before the first cure of vaccination were more likely to do with COVID- 19 vaccination and tolerate vaccination without complication.